Abstracts tagged "Abatacept"

Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Rieke Alten¹, HM Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, J Heitzmann⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
Abstract Number: 419 • 2017 ACR/ARHP Annual Meeting
Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience
Omar Valenzuela¹, María Paz Poblete², Claudia Mardones², Sebastián Ibáñez¹, Katherine Mogollones², Francisco Silva¹ and María José Villar², ¹Rheumatology department, Hospital Padre Hurtado, Santiago, Chile, ²Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: Since the year 2016 Rheumatoid Arthritis (RA) patients in the Chilean public health system can access biologic treatment if they have active disease refractory…
Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
B Haraoui¹, Janet E. Pope², Isabelle Fortin³, Emmanouil Rampakakis⁴, John S. Sampalis^5,6, Francoise Romeyer⁷, Joseph Atallah⁷ and Louis Bessette⁸, ¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷Bristol-Myers Squibb, Montreal, QC, Canada, ⁸Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada
Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
Abstract Number: 498 • 2017 ACR/ARHP Annual Meeting
Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
Carlos Fernández-Díaz¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto Guerrero⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez⁹, Bryan Josue Robles Flores¹⁰, Blanca Hernández-Cruz¹¹, Ana Urruticoechea-Arana¹², Olga Maiz¹³, Desiree Palma¹⁴, Luis Arboleya¹⁵, Gema Bonilla¹⁶, Manuel Rodríguez-Gómez¹⁷, Concepción Delgado¹⁸, Rosa Expósito¹⁹, Ana Ruibal Escribano²⁰, Juan Blanco Madrigal²¹, José Antonio Bernal²², Paloma Vela²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Javier Narváez²⁶, Manuel Jose Moreno²⁷, Mireia López-Corbeto²⁸, Natalia Mena-Vazquez²⁹, S. Romero-Yuste³⁰, Clara Aguilera-Cros³¹, Sergi Ordoñez³², Ignacio Villa-Blanco³³, Nuria Vegas-Revenga¹, Victor Mora-Cuesta³⁴, Javier Loricera¹, Miguel Angel González-Gay¹, José Luis Hernandez³⁵ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁵Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de León, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹H. German Trias., Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹²Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹³Hospital Donostia. Spain, San Sebastian, Spain, ¹⁴Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁵Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸H. Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²⁰Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²¹Rheumatology, Hospital de Basurto, BIlbao, Spain, ²²Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ²³Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²⁷Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁸Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²⁹Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³⁰H. Pontevedra, Pontevedra, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Hospital Universitario Arnau de Vilanova, Vilanova, Spain, ³³Hospital de Sierrallana, Sierrallana, Spain, ³⁴Neumology, Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain, ³⁵Division of Internal Medicine., Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain
Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…
Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting
Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis
Mayumi Matsuda¹, Yu Funakubo Asanuma², Noritsune Kouzu³ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Saitama Medical University, Moroyama, Japan
Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…
Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting
Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition
Eun Ha Kang¹, Yinzhu Jin², Sara Dejene³, Gregory Brill³, Rishi J. Desai², Jeffrey A. Sparks⁴ and Seoyoung C. Kim⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting
Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
Abstract Number: 527 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Abatacept in Patients with Rheumatoid Arthritis: A Multi-Database Study
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers², Sara Gale³, Micki Klearman³, Khaled Sarsour³ and Sebastian Schneeweiss², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Genentech, South San Francisco, CA
Background/Purpose: While tocilizumab (TCZ) may increase serum lipid levels, recent studies do not suggest an increased cardiovascular (CV) risk associated with TCZ use compared to…
Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Hermine I. Brunner¹, N Ruperto², G Vega-Cornejo³, A Berman⁴, Inmaculada Calvo⁵, R Cuttica⁶, F Ávila-Zapata⁷, Michael Henrickson¹, DJ Kingsbury⁸, D Viola⁹, V Keltsev¹⁰, K Minden¹¹, John F. Bohnsack¹², X Li¹³, M Nys¹⁴, R Wong¹³, S Banerjee¹³, Daniel J Lovell¹ and Alberto Martini¹⁵, ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁷Star Medica Hospital, Yucatán, Mexico, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹CAICI Institute, Rosario City, Santa Fe State, Argentina, ¹⁰GBUZ Samara region "Togliatti City Clinical Hospital No.5" Rheumatology Department, Togliatti, Russian Federation, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²University of Utah School of Medicine, Salt Lake City, UT, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…
Abstract Number: 540 • 2017 ACR/ARHP Annual Meeting
Being Elderly Is Not a Predictive Factor of Discontinuation of Abatacept Due to Adverse Events in Rheumatoid Arthritis Patients with Concomitant Methotrexate: A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Nobunori Takahashi, Toshihisa Kojima, Shuji Asai, Tatsuo Watanabe, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue and Naoki Ishiguro, Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Abatacept is a new class of biologic agent for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to CD80/86.…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 560 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome
Gwenny M. Verstappen¹, Johan Bijzet¹, Jolien F. van Nimwegen¹, Martha S. van Ginkel¹, Arjan Vissink², Hendrika Bootsma¹ and Frans G.M. Kroese¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains…
Abstract Number: 2891 • 2017 ACR/ARHP Annual Meeting
Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases
E Alemao, Z Guo and L Burns, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Data on the association between RA and type 2 diabetes mellitus (T2DM) are inconsistent, suggesting RA treatments such as glucocorticoids (GCs) and hydroxychloroquine could…
Abstract Number: 608 • 2017 ACR/ARHP Annual Meeting
Presence of Poor Prognostic Factors May Predict Response to Abatacept in Patients with Active Psoriatic Arthritis: Results from a Post Hoc Analysis from a Phase III Study
Philip J Mease¹, Iain B. McInnes², Vibeke Strand³, O FitzGerald⁴, H Ahmad⁵, A Johnsen⁵, J Ye⁵ and S Banerjee⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, Great Britain, ³Stanford University, Palo Alto, CA, ⁴Department of Rheumatology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, significantly increased ACR20 response and had an overall beneficial effect on musculoskeletal symptoms in patients with active psoriatic…
Abstract Number: 2964 • 2017 ACR/ARHP Annual Meeting
Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI
Edward C. Keystone¹, H Ahmad², Yusuf Yazici³, X Liu² and MJ Bergman⁴, ¹University of Toronto, Toronto, ON, Canada, ²Bristol-Myers Squibb, Princeton, NJ, ³New York University School of Medicine, New York, NY, ⁴Drexel University College of Medicine, Philadelphia, PA
Background/Purpose: Clinicians rely on time-efficient, validated disease activity assessments to help accurately predict disease progression in patients with RA. The utility of the Routine Assessment…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].